Abstract Library

#4632 MEN1 associated pancreatic neuroendocrine tumours: Re-evaluating the 2cm cut-off for surgical resection

Introduction: Pancreatic neuroendocrine tumours (PanNETs) are the leading cause of death in patients (pts) with MEN1. Screening is recommended to diagnose early and prevent metastases. The optimal cut-off of when to intervene in a PanNET is still an area of debate.

Conference:

Presenting Author: Frydman A

Authors: Frydman A, Clement D, Srirajaskanthan R,

Keywords: MEN1, Pan NET,

#4593 Excellent response to Ac-225 DOTATATE therapy in a patient with small cell lung cancer

Introduction: Peptide receptor radionuclide therapy (PRRT) is a validated treatment for patients with NETs overexpressing somatostatin receptors (SSTR). IHC analysis indicates that up to 50% of small cell lung cancer (SCLC) tumours are SSTR2 positive and thus can be targeted by SSR imaging and PRRT. Therapy with α-emitting radionuclides, such as Ac225, may offer several advantages over β-emitters by having higher energy transfer and more effective cancer cell death.

Conference:

Presenting Author: Tuncel M

Authors: Tuncel M, Türkan C, Eryılmaz Y, Pala A, Kılıçkap S,

Keywords: Ac-225 DOTATATE, Small Cell lung cancer, PET, somatostatin receptor, PRRT,

#4566 Predictive value of high-risk histopathological- and molecular criteria for lymph node metastasis in appendiceal neuroendocrine tumours

Introduction: Appendiceal neuroendocrine tumours (aNET) are rare neoplasms for which consensus is needed for follow-up and additional treatment. To unravel the factors behind aNET which showed lymph node metastasis (LNM) in additional right hemicolectomy (RH), we evaluated high-risk histopathological parameters in aNETs and studied molecular parameters.

Conference:

Presenting Author: Bremer B

Authors: Bremer B, Kyriskozoglou V, El Moumni M, Heideman D, Walenkamp-Hageman A,

Keywords: Appendix NET, High-risk histopathological criteria, Serotonin, Driver mutation, Right Hemicolectomy,

#4561 Prognostic value of pre-therapeutic and interim SSTR PET in patients with GI-NET receiving peptide receptor radionuclide therapy

Introduction: Baseline and interim (after 2 cycles) somatostatin receptor (SSTR)-directed PET/CTs are essential in patients with gastrointestinal neuroendocrine tumours (GI-NET) undergoing peptide radioreceptor therapy (PRRT).

Conference:

Presenting Author: Weber S

Authors: Weber S, Alwers S, Beissert M, Buck A, Werner R,

Keywords: somatostatin, PRRT, PFS, SUVmean,

#4560 Genetic trajectory and clonal evolution of non-functional pancreatic neuroendocrine tumours with lymph node and liver metastasis

Introduction: The systemic spread of panNETs is dominated by lymphatic reflux and portal system, exhibiting diverse patterns of metastasis without systematical genomic investigation.

Conference:

Presenting Author: Wu J

Authors: Wu J, Peng Y, Yin L, Jiang K, Li Q,

Keywords: Pan NET, Metastasis, Whole exome sequencing, Pylogenic tree,